Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1
ContributorsNAMSAL ANRS 12313 Study Group
CollaboratorsCalmy, Alexandra
Published inNew England Journal of Medicine, vol. 381, no. 9, p. 816-826
Publication date2019
Abstract
Keywords
- Adult
- Benzoxazines/administration & dosage/adverse effects
- Drug Therapy, Combination
- Female
- HIV Infections/drug therapy
- HIV Integrase Inhibitors/adverse effects/therapeutic use
- HIV-1/genetics/isolation & purification
- Heterocyclic Compounds, 3-Ring/administration & dosage/adverse effects
- Humans
- Lamivudine/administration & dosage
- Male
- Obesity/chemically induced
- Pregnancy
- RNA, Viral/blood
- Tenofovir/administration & dosage
- Viral Load/drug effects
- Weight Gain/drug effects
Affiliation
Research group
Funding
- Autre - ANRS 12313
Citation (ISO format)
NAMSAL ANRS 12313 Study Group. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. In: New England Journal of Medicine, 2019, vol. 381, n° 9, p. 816–826. doi: 10.1056/NEJMoa1904340
Main files (1)
Article (Published version)
Identifiers
- PID : unige:145652
- DOI : 10.1056/NEJMoa1904340
- PMID : 31339676
ISSN of the journal0028-4793
